AbbVie collaborates with ReGenX Biosciences on the surabgene lomparvovec treatment platform, which is relevant to patients receiving Novartis' ZOLGENSMA®.

The entities involved

• AbbVie →

  pharmaceutical company

  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
  • AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
• ReGenX Biosciences (United States) →

  company in Washington D.C., United States

  Nothing else this week.

• Novartis →

  Swiss-American multinational pharmaceutical corporation

  • Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
  • GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16

Related events

• Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Sep 9
• Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.Jun 7
• The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.Aug 6
• The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Sep 14
• Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.Sep 15